Skip to Main Content

Paper Details

Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.
Clin Infect Dis
5
2023
BA, BA., BA.4, Coronavirus, Omicron, RNA (mRNA, SARS, SARS-CoV-2, Severe, Severe Acute Respiratory Syndrome Coronavirus, severe, severe acute
Author NameAffiliation
Nadine RouphaelEmory University Hope Clinic
Sharon E FreySaint Louis University, Center for Vaccine Development
Susan J LittleUniversity of California San Diego
Jennifer A WhitakerBaylor College of Medicine
Paul A GoepfertUniversity of Alabama at Birmingham
David C MontefioriDuke University
  • 1 - 6

Datasets

Release 1.2